Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of severe chronic pain in adults. The company sells RYZOLT primarily in the United States, Europe, Canada, South Korea, and Australia. Labopharm's products in pipeline include once-daily formulation of trazodone, a serotonin antagonist reuptake inhibitor for the treatment of depressive disorder. Its product candidates in clinical development based on Contramid platform comprise twice-daily formulation of tramadol plus acetaminophen to address acute pain; and Abuse Deterrent Platform to provide safer medications through resistance to the uncontrolled release of the active ingredient after actions, such as breaking, chewing, crushing and heating, or consumption with alcohol. Its product candidates in clinical development based on the Polymeric Nano-Delivery System platform comprise lipid-and preservative-free formulation of the intravenous anaesthetic agent propofol; and SN-38, which is the active metabolite in the prescribed intravenous colon cancer drug irinotecan.

U.S. Genomics, Inc. company has developed the GeneEngine, a DNA sequencer that mimics natural cell division, rapidly reading and copying DNA. It is developing the technology to quickly detect and identify infectious pathogens and biomarkers for biodefense and diagnostic use. Its products can detect and quantify molecules of DNA, RNA, and proteins without amplification. Backed by private equity investors and biomedical firms including Becton Dickinson, U.S. Genomics has netted contracts with the Department of Homeland Security. Northrup Gruman is the company's bio-security development partner.

Nippon Kayaku Co., Ltd. company is divided into three primary business lines: functional chemicals, pharmaceuticals, and automotive safety parts (airbags, ignition parts). It also manufactures pesticides and herbicides. Its pharmaceuticals segment is focused on producing anti-cancer drugs and immunosuppressants as well as cardiovascular and neurological drugs (brand name and generics). Other products in its divisions include dyes, inflators for automobile airbags, industrial explosives, epoxy resins, and agricultural chemicals. Nippon Kayaku has offices, manufacturing plants, and laboratories in Japan, as well as operations in China, Germany, Taiwan, and the US.

Dainippon Sumitomo Pharma (DSP) is Osaka's answer to disease. The Japanese drugmaker produces drugs in a wide range of therapeutic categories including cardiovascular disease, gastrointestinal disorders, and infections. Its products include blood pressure medication Amlodin, digestive tract treatment Gasmotin, and antibiotic Meropen. Subsidiary Sepracordevelops and markets central nervous system and respiratory drugs in North America; its top selling product is insomnia therapy Lunesta. In addition to pharmaceuticals, DSP makes food and feed additives, veterinary drugs, fine chemicals, and diagnostic reagents used in research and clinical laboratories. Sumitomo Chemical owns just over half of DSP.

DOV Pharmaceutical, Inc. is a biopharmaceutical company focused on the development of product candidates for disorders of the central nervous system (CNS). The Company has drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The Company also has a drug development program subject to regulatory review, Indiplon, which is being developed as a treatment for insomnia. The Company has sublicensing agreements for the development and commercialization of certain product candidates with XTL Biopharmaceuticals, Inc. (XTL) for bicifadine, with Blue Note Pharmaceuticals, Inc. (Blue Note) for DOV diltiazem, and with Neurocrine Biosciences, Inc. (Neurocrine) for indiplon.

Roche Holding (UK) is the holding company for Roche Products Limited and Roche Diagnostics Limited. The two UK subsidiaries develop and manufacture various products and equipment for the diagnosis and treatment of disease. Its pharmaceuticals include Copegus, a hepatitis C therapy; HIV inhibitor Fuzeon; and breast cancer therapy Herceptin. The firm's diagnostics arm makes a variety of consumer and professional tests, including Accu-Chek glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics.

Eurand, Inc. company, a subsidiary of Netherlands-based Eurand N.V., develops drug delivery technologies to help drugmakers improve the efficacy of their products. Eurand researches and manufactures drugs marketed in the Americas and Europe, mostly through partnerships with other pharma companies. Eurand's drug delivery systems include Biorise to make certain drugs water soluble; Diffucaps and Minitabs to control the release of drug components as they make their way through the digestive system; and AdvaTab and Liquitard to mask the taste of medicines. The company also conducts research for its parent's own portfolio of drugs under development.

Instrumentation Laboratory Company develops and manufactures diagnostic medical equipment primarily for hospitals and clinical laboratories around the globe. The company provides critical care systems, hemostasis products, and information management services. Its product lines include GEM and Synthesis analyzers for critical care diagnostics, and ACL and HemosIL analyzers and reagents for automated clot-timing testing. Its products are marketed through global affiliates and third-party distributors. Instrumentation Laboratory was established in 1959 and is a division of private Spanish health care company Werfen Group.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide. It develops, produces, markets, and distributes therapies for the people suffering from chronic and acute, immune deficiency disorders, alpha-1 antitrypsin deficiency, infectious diseases, hemophilia, and severe burns. The company's products include Gamunex, an intravenous immune globulin (IGIV) for the treatment of primary immune deficiency and autoimmune diseases; and Prolastin, an alpha-1 proteinase inhibitor (A1PI) for the treatment of alpha-1 antitrypsin deficiency-related emphysema. It also offers Hypermunes, which are antibody preparations for hepatitis, rabies, tetanus, and treatment of Rh negative women pregnant with Rh positive children; and albumin under various brand names, including Plasbumin albumin and Plasmanate plasma protein factor. Talecris Biotherapeutics Holdings Corp. is headquartered in Research Triangle Park, North Carolina.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.